Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection

J Antimicrob Chemother. 2017 Feb;72(2):632-633. doi: 10.1093/jac/dkw439. Epub 2016 Oct 17.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / adverse effects
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • Cobicistat / administration & dosage
  • Cobicistat / adverse effects
  • Cobicistat / therapeutic use
  • Emtricitabine / administration & dosage
  • Emtricitabine / adverse effects
  • Emtricitabine / therapeutic use
  • HIV / drug effects*
  • HIV / genetics
  • HIV Infections / diagnosis
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Male
  • Middle Aged
  • Quinolones / administration & dosage
  • Quinolones / adverse effects
  • Quinolones / therapeutic use
  • Retrospective Studies
  • Tenofovir / administration & dosage
  • Tenofovir / adverse effects
  • Tenofovir / therapeutic use
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Anti-HIV Agents
  • Quinolones
  • elvitegravir
  • Tenofovir
  • Emtricitabine
  • Cobicistat